Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices

Report Overview

In this report, biopharmaceutical manufacturer decision-makers share their perspectives on:

• Expected outsourcing of commercial biosimilar manufacturing
• Comfort level with outsourcing to individual CMOs
• Market trends and biosimilar manufacturing method preferences

How you can use this report:

Sponsors

• Stay on top of industry trends by learning what biopharmaceutical companies currently manufacturing large molecules think the future holds for biosimilar manufacturing
• Learn what methods of biosimilar manufacturing peers are gravitating towards
• Understand where, geographically, biopharmaceutical companies are looking to manufacturer biosimilars

CMOs

• Start to understand the market potential for outsourced biosimilar manufacturing
• Learn what biopharmaceutical companies would value from a CMO and leverage these drivers in your sales and marketing efforts
• Get an early indication of market leaders by knowing which manufacturers and CMOs respondents would be most comfortable using for biosimilar production

Methodology:

ISR conducted 68 online quantitative surveys with respondents from biopharmaceutical companies who:

• Have significant influence over outsourced commercial manufacturing activities
• Have been involved in outsourcing commercial manufacturing activities within the past 18 months